• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Jim Cramer Weighs In On Carnival, Canadian Pacific Railway And More

    12/2/21 7:37:22 AM ET
    $CCL
    $CP
    $DCRC
    $FLGT
    Marine Transportation
    Consumer Discretionary
    Railroads
    Industrials
    Get the next $CCL alert in real time by email

    On CNBC’s "Mad Money Lightning Round," Jim Cramer said Fulgent Genetics, Inc. (NASDAQ:FLGT) is a "mystery" to him. With the company doing quite well, he considers it a very good company.

    When asked about Carnival Corporation (NYSE:CCL), Cramer said he likes Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) as it has the best balance sheet: “Maybe we can go down to Carnival later," he said.

    The "Mad Money" host said Canadian Pacific Railway Limited (NYSE:CP) is a "rail that’s come down so far." He recommends buying the stock in case the economy rebounds again.

    Cramer said the SEC is investigating Cassava Sciences, Inc. (NASDAQ:SAVA), according to Dow Jones. "Until I see more about that, I’m going to hold off pronouncing anything about Cassava," he added.

    He said that Insmed Incorporated (NASDAQ:INSM) is a pure speculative stock and nothing beyond that.

    Cramer said Decarbonization Plus Acquisition Corporation III (NASDAQ:DCRC) is a speculative stock.

    "It’s a SPAC, none of them seem to be working right now, but it’s a great stock in principle, how about that," he added.

    Get the next $CCL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CCL
    $CP
    $DCRC
    $FLGT

    CompanyDatePrice TargetRatingAnalyst
    Norwegian Cruise Line Holdings Ltd.
    $NCLH
    2/13/2026$20.00Overweight → Neutral
    Analyst
    Norwegian Cruise Line Holdings Ltd.
    $NCLH
    2/11/2026$23.00Overweight → Equal Weight
    Barclays
    Insmed Incorporated
    $INSM
    1/28/2026$231.00Overweight
    Barclays
    Insmed Incorporated
    $INSM
    1/23/2026$212.00Buy
    Roth Capital
    Norwegian Cruise Line Holdings Ltd.
    $NCLH
    1/20/2026$40.00 → $28.00Overweight
    Analyst
    Insmed Incorporated
    $INSM
    12/19/2025$202.00Buy
    Truist
    Norwegian Cruise Line Holdings Ltd.
    $NCLH
    12/15/2025$20.00Buy → Hold
    Jefferies
    Norwegian Cruise Line Holdings Ltd.
    $NCLH
    12/9/2025$21.00Buy → Neutral
    Goldman
    More analyst ratings

    $CCL
    $CP
    $DCRC
    $FLGT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Vessel Ops & NO Dahlgren Patrik bought $99,578 worth of shares (5,550 units at $17.94), increasing direct ownership by 4% to 144,817 units (SEC Form 4)

    4 - Norwegian Cruise Line Holdings Ltd. (0001513761) (Issuer)

    11/25/25 4:15:09 PM ET
    $NCLH
    Marine Transportation
    Consumer Discretionary

    Director Anderson Robert Eugene Jr bought $24,940 worth of shares (8,600 units at $2.90) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/25/25 4:06:25 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President & CEO Barry Richard bought $414,000 worth of shares (150,000 units at $2.76) (SEC Form 4)

    4 - CASSAVA SCIENCES INC (0001069530) (Issuer)

    11/24/25 4:02:17 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CCL
    $CP
    $DCRC
    $FLGT
    SEC Filings

    View All

    Canadian Pacific Kansas City Limited filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

    8-K - CANADIAN PACIFIC KANSAS CITY LTD/CN (0000016875) (Filer)

    3/6/26 4:30:17 PM ET
    $CP
    Railroads
    Industrials

    SEC Form 144 filed by Insmed Incorporated

    144 - INSMED Inc (0001104506) (Subject)

    3/5/26 4:59:55 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Canadian Pacific Kansas City Limited

    8-K - CANADIAN PACIFIC KANSAS CITY LTD/CN (0000016875) (Filer)

    3/4/26 9:36:15 PM ET
    $CP
    Railroads
    Industrials

    $CCL
    $CP
    $DCRC
    $FLGT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Norwegian Cruise Line downgraded by Analyst with a new price target

    Analyst downgraded Norwegian Cruise Line from Overweight to Neutral and set a new price target of $20.00

    2/13/26 8:29:21 AM ET
    $NCLH
    Marine Transportation
    Consumer Discretionary

    Norwegian Cruise Line downgraded by Barclays with a new price target

    Barclays downgraded Norwegian Cruise Line from Overweight to Equal Weight and set a new price target of $23.00

    2/11/26 7:50:17 AM ET
    $NCLH
    Marine Transportation
    Consumer Discretionary

    Barclays initiated coverage on Insmed with a new price target

    Barclays initiated coverage of Insmed with a rating of Overweight and set a new price target of $231.00

    1/28/26 7:17:09 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CCL
    $CP
    $DCRC
    $FLGT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $CCL
    $CP
    $DCRC
    $FLGT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    $CCL
    $CP
    $DCRC
    $FLGT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Chair and CEO Lewis William exercised 10,699 shares at a strike of $24.94 and sold $1,562,328 worth of shares (10,699 units at $146.03) (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    3/5/26 4:16:51 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sharoky Melvin Md gifted 100 shares, decreasing direct ownership by 0.04% to 242,776 units (SEC Form 4)

    4 - INSMED Inc (0001104506) (Issuer)

    3/5/26 4:15:10 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SVP & Chief Accounting Officer Ashby Faye L. covered exercise/tax liability with 8,213 shares, decreasing direct ownership by 6% to 122,157 units (SEC Form 4)

    4 - Norwegian Cruise Line Holdings Ltd. (0001513761) (Issuer)

    3/3/26 4:15:40 PM ET
    $NCLH
    Marine Transportation
    Consumer Discretionary

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-13) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 06/01/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    6/2/23 4:38:39 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for ARIKAYCE KIT issued to INSMED INC

    Submission status for INSMED INC's drug ARIKAYCE KIT (SUPPL-12) with active ingredient AMIKACIN SULFATE has changed to 'Approval' on 02/10/2023. Application Category: NDA, Application Number: 207356, Application Classification: Labeling

    2/13/23 4:39:32 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    BRIDGEWATER, N.J., March 5, 2026 /PRNewswire/ -- Insmed Incorporated (NASDAQ:INSM), a people-first global biopharmaceutical company striving to deliver first- and best-in-class therapies to transform the lives of patients facing serious diseases, today announced the granting of inducement awards to 85 new employees. The awards were granted under the Insmed Incorporated 2025 Inducement Plan, which is intended to meet the requirements of a plan providing for inducement grants under Nasdaq Listing Rule 5635(c)(4). The awards were approved by Insmed's Compensation Committee and made as a material inducement to each employee's entry into employment with the Company.In connection with the commence

    3/5/26 7:00:00 AM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CPKC announces US $1.2 billion debt offering

    CALGARY, AB, March 4, 2026 /CNW/ - Canadian Pacific Kansas City Limited (TSX:CP) (NYSE:CP) ("CPKC") announced that its wholly-owned subsidiary, Canadian Pacific Railway Company, is issuing US $600 million of 4.000% Notes due 2029 and US $600 million of 5.500% Notes due 2056, which will be guaranteed by CPKC.The offering is expected to close on March 6, 2026, subject to the satisfaction of customary closing conditions.The net proceeds from the offering will be used primarily for the refinancing of outstanding indebtedness and for general corporate purposes. Until utilized for such purposes, the net proceeds may be invested in short term investment grade securities or bank deposits.The joint a

    3/4/26 6:27:00 PM ET
    $CP
    Railroads
    Industrials

    SEABOURN INTRODUCES "YOURS TO EXPLORE EVENT," OFFERING SUITE UPGRADES AND SHIPBOARD CREDIT ON SELECT 2026 AND BEYOND VOYAGES

    Complimentary Two-Category Veranda Suite Upgrades and Shipboard Credit Available on More than 500 Ocean and Expedition Sailings Booked Through May 5, 2026SEATTLE, March 4, 2026 /PRNewswire/ -- Seabourn, the leader in luxury and expedition travel, invites travelers to embrace a world of curated luxury with its new "Yours to Explore Event." Available now through May 5, 2026, the promotion will offer a complimentary two-category Veranda Suite upgrade and shipboard credit for guests booking select 2026 and beyond ocean and expedition voyages. Benefits for the "Yours to Explore Event

    3/4/26 3:52:00 PM ET
    $CCL
    $CUK
    Marine Transportation
    Consumer Discretionary

    $CCL
    $CP
    $DCRC
    $FLGT
    Leadership Updates

    Live Leadership Updates

    View All

    CPKC debuts 1776 locomotive to celebrate America's 250th anniversary

    KANSAS CITY, Mo., March 3, 2026 /CNW/ - Canadian Pacific Kansas City (TSX:CP) (NYSE:CP) (CPKC) today unveiled a commemorative locomotive livery honoring the 250th anniversary of the Declaration of Independence and celebrating the founding of the United States of America.  "This locomotive, built and painted in Fort Worth, Texas, honors the remarkable and proud history of America as we prepare to mark the nation's 250th anniversary," said Keith Creel, CPKC President and Chief Executive Officer. "As a U.S. Army veteran, I am proud to join my 6,000 fellow railroaders living and working across America in celebrating the contributions of all Americans throughout our history. Together, we join the

    3/3/26 2:30:00 PM ET
    $CP
    Railroads
    Industrials

    Norwegian Cruise Line Holdings Appoints John W. Chidsey as President and Chief Executive Officer

    MIAMI, Feb. 12, 2026 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH), a leading global cruise company operating Norwegian Cruise Line, Oceania Cruises, and Regent Seven Seas Cruises, today announced that its Board of Directors has appointed John W. Chidsey, a director of NCLH, as President and Chief Executive Officer, effective immediately. Mr. Chidsey succeeds Harry Sommer, who is stepping down as President and Chief Executive Officer and as a Director of NCLH. Mr. Chidsey has a proven track record of leading large global consumer-facing companies through strategic and operational transformation, with experience across franchised operating models, as well as yield-dri

    2/12/26 4:15:00 PM ET
    $NCLH
    Marine Transportation
    Consumer Discretionary

    Oceania Cruises® Celebrates Keel Laying for New-Generation Ship, Oceania Sonata™, at the Fincantieri Shipyard in Marghera, Italy

    Oceania Sonata is the First of Four New Sonata Class Vessels for the Luxury Line MIAMI, Feb. 5, 2026 /PRNewswire/ -- Oceania Cruises®, the world's leading culinary- and destination-focused luxury cruise line, has celebrated a pivotal milestone in the construction of its next-generation ship, Oceania Sonata™, as the keel of the ship was laid at the Fincantieri shipyard in Marghera, Italy. The ceremony, an important maritime tradition, honored the rich heritage of shipbuilding, the importance of partnership, and underscored the line's bold vision of its future. "Oceania Sonata e

    2/5/26 8:30:00 AM ET
    $NCLH
    Marine Transportation
    Consumer Discretionary

    $CCL
    $CP
    $DCRC
    $FLGT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Insmed Incorporated

    SC 13G/A - INSMED Inc (0001104506) (Subject)

    11/14/24 1:22:37 PM ET
    $INSM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Fulgent Genetics Inc.

    SC 13D/A - Fulgent Genetics, Inc. (0001674930) (Subject)

    11/5/24 4:46:55 PM ET
    $FLGT
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Cassava Sciences Inc.

    SC 13G/A - CASSAVA SCIENCES INC (0001069530) (Subject)

    11/4/24 4:09:49 PM ET
    $SAVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CCL
    $CP
    $DCRC
    $FLGT
    Financials

    Live finance-specific insights

    View All

    CPKC announces US $1.2 billion debt offering

    CALGARY, AB, March 4, 2026 /CNW/ - Canadian Pacific Kansas City Limited (TSX:CP) (NYSE:CP) ("CPKC") announced that its wholly-owned subsidiary, Canadian Pacific Railway Company, is issuing US $600 million of 4.000% Notes due 2029 and US $600 million of 5.500% Notes due 2056, which will be guaranteed by CPKC.The offering is expected to close on March 6, 2026, subject to the satisfaction of customary closing conditions.The net proceeds from the offering will be used primarily for the refinancing of outstanding indebtedness and for general corporate purposes. Until utilized for such purposes, the net proceeds may be invested in short term investment grade securities or bank deposits.The joint a

    3/4/26 6:27:00 PM ET
    $CP
    Railroads
    Industrials

    Norwegian Cruise Line Holdings Reports Fourth Quarter and Full Year 2025 Financial Results

    MIAMI, March 02, 2026 (GLOBE NEWSWIRE) -- Norwegian Cruise Line Holdings Ltd. (NYSE:NCLH) (together with NCL Corporation Ltd. ("NCLC"), "Norwegian Cruise Line Holdings", "Norwegian", "NCLH" or the "Company") today reported financial results for the fourth quarter and full year ended December 31, 2025, and provided guidance for the first quarter and full year 2026. Highlights Grew total revenue 3.7% to $9.8 billion in 2025. GAAP net income was $423.2 million, with EPS of $0.92.Delivered Adjusted EBITDA1 of $2.73 billion in 2025, exceeding guidance, and representing an increase of 11% compared to 2024. Adjusted Net Income grew 15% to $1.045 billion. Adjusted EPS grew 19% to $2.11.Company s

    3/2/26 6:30:00 AM ET
    $NCLH
    Marine Transportation
    Consumer Discretionary

    Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results

    Revenue of $83.3 million, growing 9% year-over-year GAAP gross profit of $32.6 million, or GAAP gross margin of 39.1%; Non-GAAP gross profit of $34.2 million, or Non-GAAP gross margin of 41.0% GAAP loss of $23.4 million, or ($0.76) per share; Non-GAAP income of $5.2 million, or $0.16 per share Ended the year with $705.5 million of cash, cash equivalents, restricted cash, and investments in marketable securities, excluding an anticipated tax refund of approximately $106.3 million Fulgent Genetics, Inc. (NASDAQ:FLGT) ("Fulgent," or the "Company"), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announce

    2/27/26 7:00:00 AM ET
    $FLGT
    Medical Specialities
    Health Care